Umoja Biopharma
Umoja Biopharma develops in vivo CAR T cell therapies that generate cancer-fighting T cells directly in a patient’s body. Its therapies are designed to treat cancers while making treatment more accessible by avoiding the multi-week cell manufacturing required for ex vivo CAR T therapies.
Facts
- HQ
- Seattle, WA 98109
- Sectors
- Biotechnology Research
- Founded
- 2019
- Type
- Corporation Seattle business license
- Employees
- 254
- Registered name
- Umoja Biopharma Inc Seattle business license
- Members see funding amounts. .
Is this your organization? Claim it
BrainChild Bio Raises $116M Series A on Sept. 8 to Fund Phase 2 B7-H3 CAR T Trial for DIPG
BrainChild Bio raised $116 million in a Series A on Sept. 8 to fund a registrational Phase 2 trial of BCB-276, a B7-H3 CAR T therapy delivered directly into cerebrospinal fluid for DIPG, and to advance a triple-antigen glioblastoma program. The Seattle Children’s spinout aims to bypass the blood-brain barrier with intrathecal delivery after promising early survival signals.
BrainChild Bio raises $116M Series A to fund Phase 2 CAR T trial for childhood DIPG
Seattle startup BrainChild Bio raised $116 million in Series A funding to advance a CAR T cell therapy for diffuse intrinsic pontine glioma (DIPG) and to support development of additional pediatric and adult brain tumor CAR T programs. The financing will fund a pivotal ILLUMINATE Phase 2 registration-stage trial and was led by an undisclosed private family fund and foundation, with participation from Seattle Children’s and WRF Capital.
BrainChild Bio raises $116M Series A to fund Phase 2 CAR‑T trial for pediatric diffuse intrinsic pontine glioma
BrainChild Bio raised $116 million in Series A financing to advance CAR-T therapies into the central nervous system, funding a Phase 2 trial of its lead candidate for pediatric diffuse intrinsic pontine glioma while planning future adult indications.
See all 18 stories, episodes and videos about Umoja Biopharma.
Seattle Flow is free for everyone.
- Claim and edit your profile
- Get alerts about you, your company, and anything else you care about
- Access the most comprehensive investor list in Seattle
- Join the conversation on news, podcasts, and events
People
-
Andy Scharenberg Executive Officer, Director, Co-founder & Chief Executive Officer
-
Michael Jensen Co-Founder
-
Nate Hardy Executive, Chief Financial Officer